Comparison of bortezomib-cyclophosphamide-dexamethasone <em>versus</em> bortezomib-dexamethasone based regimens in newly diagnosed multiple myeloma patients

Comparison of bortezomib-cyclophosphamide-dexamethasone <em>versus</em> bortezomib-dexamethasone based regimens in newly diagnosed multiple myeloma patients

The treatment landscape and clinical outcome of multiple myeloma (MM) patients have changed in the last decades, with an improved median survival of 8-10 years. This study aimed to evaluate the bortezomib, cyclophosphamide and dexamethasone (VCD) regimen versus bortezomib and dexamethasone (VD) regi...

Full description

Bibliographic Details
Main Authors: Rafiye Ciftciler, Hakan Goker, Yahya Buyukasik, Nilgun Sayınalp, Ibrahim C. Haznedaroglu, Salih Aksu, Osman Ozcebe, Haluk Demiroglu
Format: Article
Language:English
Published: MDPI AG 2020-05-01
Series:Hematology Reports
Subjects:
Multiple myeloma
VD regimen
VCD regimen
Online Access:https://www.pagepress.org/journals/index.php/hr/article/view/8267

Internet

https://www.pagepress.org/journals/index.php/hr/article/view/8267

Similar Items